Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"The effects of prune products consumption on anthropometric measurements and blood pressure in adults: A systematic review and dose-response meta-analysis","authors":"Azadeh Heydarian ,&nbsp;Shima Moradi ,&nbsp;Omid Asbaghi ,&nbsp;Negin Tahvilian ,&nbsp;Sahar Cheshmeh ,&nbsp;Maryam Nadery ,&nbsp;Naheed Aryaeian","doi":"10.1016/j.dsx.2024.103173","DOIUrl":"10.1016/j.dsx.2024.103173","url":null,"abstract":"<div><h3>Introduction</h3><div>The positive impact of prunes on body measurements and blood pressure has been suggested in previous research.</div></div><div><h3>Purpose</h3><div>The purpose of this extensive meta-analysis and systematic review was to examine the effects of adult consumption of prunes on anthropometric parameters and blood pressure.</div></div><div><h3>Methods</h3><div>To identify relevant randomized controlled trials (RCTs) (till August 9th, 2024), databases from ISI Web of Science, Scopus, and PubMed/Medline were searched. The current systematic review and meta-analysis covered 14 studies that met the eligibility requirements. The weighted mean difference was used to compute the effect size. The Cochrane Q test and I2 index were used to measure study heterogeneity. The random effects model was utilized to get the overall effect magnitude.</div></div><div><h3>Results</h3><div>The meta-findings analysis's showed that eating prunes had no appreciable effects on, body mass index (BMI) (p = 0.267), waist circumference (WC) (p = 0.562), fat mass (FM) (p = 0.840), systolic blood pressure (SBP) (p = 0.338), or diastolic blood pressure (DBP) (p = 0.233). However, we observed significantly reduction in body weight (p &lt; 0.001) after prunes consumption.</div></div><div><h3>Conclusion</h3><div>Our findings showed that the consumption of prune leads to a significant reduction in body weight, but the results indicated non-significant effects on blood pressure, BMI, WC and FM.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103173"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) ,&nbsp;Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2025.103192","DOIUrl":"10.1016/j.dsx.2025.103192","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103192"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143170956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","authors":"Yuming Sun ,&nbsp;Qian zhou ,&nbsp;Lorraine Edna Onzere ,&nbsp;Yating Dian ,&nbsp;Yu Meng ,&nbsp;Daishi Li ,&nbsp;Furong Zeng ,&nbsp;Shaorong Lei ,&nbsp;Guangtong Deng","doi":"10.1016/j.dsx.2025.103186","DOIUrl":"10.1016/j.dsx.2025.103186","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the causal association of using glucagon-like peptide-1 receptor (GLP1R) agonists with autoimmune diseases.</div></div><div><h3>Methods</h3><div>The available cis-eQTLs for drugs target genes (GLP1R) were used as genetic variants for exposure to GLP1R agonists. Type 2 diabetes was used as positive control. Mendelian randomizations (MR) were performed to explore the association of genetically-proxied GLP1R agonists with 11 autoimmune diseases from large-scale consortia. Replicating the findings in the FinnGen study and then pooled with meta-analysis. Finally, we performed MR analysis to examine whether GLP1R agonists affect 731 immune cell phenotypes to clarify the potential mechanism.</div></div><div><h3>Results</h3><div>We observed supportive evidence to support the association of GLP1R agonists with reduced the risk of hypothyroidism (OR [95 %] = 0.89 [0.82–0.95], <em>P</em> &lt; 0.001), but increased risk of ulcerative colitis (OR [95 %] = 1.48 [1.27–1.71], <em>P</em> &lt; 0.001), type 1 diabetes (OR [95 %] = 1.34 [1.21–1.50], <em>P</em> &lt; 0.001), systemic lupus erythematosus (OR [95 %] = 1.61 [1.29–2.02], <em>P</em> &lt; 0.001) and sarcoidosis (OR [95 %] = 1.38 [1.08–1.75], <em>P</em> = 0.008). There was no supporting evidence to verify the association of GLP1R expression with asthma, Crohn's disease, multiple sclerosis and myasthenia gravis (<em>P</em> &gt; 0.05). In addition, we found that GLP1R agonists was positively associated with 221 immune cell phenotypes (P &lt; 0.05, OR &gt; 1), and negatively associated with 317 immune cell phenotypes (P &lt; 0.05, OR &lt; 1).</div></div><div><h3>Conclusion</h3><div>GLP1R agonists are causally associated with various autoimmune diseases potentially through the modulation of 731 immune cell phenotypes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103186"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive value of estimated glucose disposal rate for all-cause and cardiovascular mortality in the US non-diabetic population aged ≥60 years: A population-based cohort study","authors":"Botao Zhu,&nbsp;Chenghui Cao,&nbsp;Wenwu Liu,&nbsp;Yuxuan Liu,&nbsp;Yonghong Luo,&nbsp;Daoquan Peng","doi":"10.1016/j.dsx.2024.103182","DOIUrl":"10.1016/j.dsx.2024.103182","url":null,"abstract":"<div><h3>Aims</h3><div>This study seeks to evaluate the prognostic significance of eGDR in predicting mortality outcomes within non-diabetic older adults.</div></div><div><h3>Methods</h3><div>8131 non-diabetic participants aged ≥60 years from the National Health and Nutrition Examination Survey (2001–2018) was included in this study. eGDR was calculated as: eGDR (mg/kg/min) = 21.158 – [0.09 × waist circumference (cm)] – [3.407 × Hypertension (Yes = 1/No = 0)] – [0.551 × HbA1c (%)]. Weighted Cox proportional hazards models, cumulative hazard curves, restricted cubic spline (RCS), and threshold effects analyses were performed to explore the relationship between eGDR and mortality outcomes. Subgroup analyses and mediation effects analyses were conducted.</div></div><div><h3>Results</h3><div>2566 all-cause deaths and 689 cardiovascular deaths were recorded. Lower eGDR was associated with higher all-cause (HR = 0.76, 95 % CI: 0.63–0.91) and cardiovascular mortality (HR = 0.56, 95 % CI: 0.40–0.80). Inflection points were identified through RCS curve analyses, and the threshold effect was significant. The eGDR-mortality association remained consistent across subgroups. Mediation analyses showed that neutrophil to high-density lipoprotein cholesterol ratio mediated the association.</div></div><div><h3>Conclusions</h3><div>Lower eGDR levels are linked to higher risk of both all-cause and cardiovascular mortality in non-diabetic older adults, suggesting its potential utility for risk assessment among this population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103182"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of lifestyle interventions on the prevention of type 2 diabetes and reversion to normoglycemia by prediabetes phenotype: A systematic review and meta-analysis of randomized controlled trials","authors":"Xin Chai ,&nbsp;Yachen Wang ,&nbsp;Xuejun Yin ,&nbsp;Qiuhong Gong ,&nbsp;Juan Zhang ,&nbsp;Ruitai Shao ,&nbsp;Guangwei Li","doi":"10.1016/j.dsx.2025.103184","DOIUrl":"10.1016/j.dsx.2025.103184","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the effects of lifestyle interventions on the prevention of type 2 diabetes (T2D) and reversion to normoglycemia by prediabetes phenotype.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) that evaluated the effects of lifestyle interventions in adults with prediabetes for a minimum duration of one year. Two reviewers independently screened articles, extracted data, and performed quality assessment. The relative effects were analyzed using a random-effects model, subgroup analysis was employed to explore the potential effects among subpopulations.</div></div><div><h3>Results</h3><div>A total of 31 RCTs involving 23684 participants were analyzed. Compared with usual care, lifestyle interventions reduced the incident T2D by 41 % (RR 0.59 [95 % CI 0.52–0.68]) and increased the probability of reverting to normoglycemia by 44 % (RR 1.44 [95 % CI 1.15–1.81]) in adults with prediabetes. No significant difference was observed between the impaired fasting glucose (IFG_5.6)/impaired glucose tolerance (IGT) and IFG_6.1/IGT (<em>P</em> = 0.752). IGT + IFG benefited more than isolated IGT in prevention of T2D (RR_IGT + IFG 0.47 [95 % CI 0.41–0.55]; RR_i_solated _IGT 0.77 [95 % CI 0.64–0.93]), whereas no benefit was found in isolated IFG (RR 0.77 [95 % CI 0.51–1.16]) or elevated HbA1c (RR 0.89 [95 % CI 0.74–1.07]).</div></div><div><h3>Conclusions</h3><div>Lifestyle intervention could help prevent T2D and revert to normoglycemia in adults with prediabetes, with significant benefit in people with IGT but not in those with isolated IFG or elevated HbA1c.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103184"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relevance of remnant cholesterol as a guide for lipid management in Indian subjects undergoing coronary revascularization","authors":"Manish Bansal ,&nbsp;Ravi R. Kasliwal ,&nbsp;Praveen Chandra ,&nbsp;Rajneesh Kapoor ,&nbsp;Nagendra Chouhan ,&nbsp;Anil Bhan ,&nbsp;Naresh Trehan","doi":"10.1016/j.dsx.2024.103183","DOIUrl":"10.1016/j.dsx.2024.103183","url":null,"abstract":"<div><h3>Background</h3><div>The atherogenic potential of remnant cholesterol, which refers to the cholesterol content of triglyceride-rich, non-low-density lipoprotein (LDL) particles in circulation, has gained increasing attention recently. Unfortunately, very limited information is available regarding remnant cholesterol levels in Indian subjects.</div></div><div><h3>Methods</h3><div>This was a retrospective study conducted at a premier, tertiary care center in North India. A total of 3064 consecutive subjects [mean age 61.3 ± 10.3 years, 2550 (83.2%) men] with newly diagnosed coronary artery disease (CAD) undergoing coronary revascularization were included. Enzymatic assays were used for measuring various lipid parameters. Remnant cholesterol was calculated by subtracting LDL cholesterol (LDL-C) and high-density lipoprotein cholesterol from total cholesterol. A value &gt;30 mg/dL was considered elevated.</div></div><div><h3>Results</h3><div>The mean LDL-C was 79.1 ± 33.1 mg/dL with 46.4% of all subjects having LDL-C &lt;70 mg/dL and only 16.9% having LDL-C &lt;50 mg/dL. The median remnant cholesterol level was 17.0 mg/dL (interquartile range 12.0–24.0 mg/dL) with only 11.9% of subjects having values &gt;30 mg/dL. Only 4.5% of the patients with LDL-C &lt;70 mg/dL and 2.9% of those with LDL-C &lt;50 mg/dL had elevated remnant cholesterol. These proportions were significantly greater in patients with serum triglycerides &gt;200 mg/dL.</div></div><div><h3>Conclusion</h3><div>Our study shows that in a North-Indian population with CAD, elevated remnant cholesterol was present in only a small proportion. The prevalence of elevated remnant cholesterol decreased further as the LDL-C control improved. These findings suggest that elevated remnant cholesterol may not be a clinically relevant therapeutic target in most patients with LDL-C below the currently recommended goals.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103183"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revised definition of obesity in Asian Indians living in India","authors":"Anoop Misra ,&nbsp;Naval K. Vikram ,&nbsp;Amerta Ghosh ,&nbsp;Piyush Ranjan ,&nbsp;Seema Gulati ,&nbsp;India Obesity Commission Members","doi":"10.1016/j.dsx.2024.102989","DOIUrl":"10.1016/j.dsx.2024.102989","url":null,"abstract":"<div><h3>Aim</h3><div>The prevailing guidelines for obesity in Asian Indians, published in 2009, relied solely on body mass index (BMI) criteria. Recognizing the limitations of BMI in accurately diagnosing obesity and the emergence of new research revealing the association between generalized and abdominal adiposity in Asian Indians and early-onset co-morbid diseases, a comprehensive redefinition was needed.</div></div><div><h3>Method</h3><div>In a Delphi process focused on obesity in India, experts were invited via email to participate in five rounds. The survey questions were administered through Google Form to gather insights from the selected experts.</div></div><div><h3>Results</h3><div>In Stage 1 Obesity, individuals exhibit increased adiposity (BMI&gt;23 kg/m²) without discernible effects on organ functions or daily activities. Stage 2 Obesity denotes a more advanced state characterized by heightened adiposity (generalized and abdominal), impacting both physical and organ functions, resulting in functional limitations during day-to-day activities, and contributing to co-morbid diseases. The criteria for Stage 2 Obesity include a mandatory BMI exceeding 23 kg/m² and at least one of the following: excess waist circumference or waist-to-height ratio. Additionally, the presence of one or more symptoms indicative of limitations in daily activities or one or more obesity-related comorbid conditions/diseases are needed to support the stage 2 obesity.</div></div><div><h3>Conclusion</h3><div>This refined framework seeks to enhance precision in identifying obesity and its associated health risks among Asian Indians living in India, and facilitation of rational management, and aligns with worldwide initiative of new definition of obesity.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 102989"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An upward trend of dyslipidemia among adult population in Vietnam: Evidence from a systematic review and meta-analysis","authors":"Anh Kim Dang ,&nbsp;Linh Thao Thi Le ,&nbsp;Ngoc Minh Pham ,&nbsp;Dung Quang Nguyen ,&nbsp;Ha Thu Thi Nguyen ,&nbsp;Son Cong Dang ,&nbsp;Anh Tuan Le Nguyen ,&nbsp;Huong Thi Le ,&nbsp;Abdullah A. Mamun ,&nbsp;Dung Phung ,&nbsp;Phong K. Thai","doi":"10.1016/j.dsx.2024.103171","DOIUrl":"10.1016/j.dsx.2024.103171","url":null,"abstract":"<div><h3>Introduction</h3><div>It is critical to assess the progress toward achieving the national goal of reducing premature mortality from non-communicable diseases (NCDs) by one-third by 2030 in Vietnam. This study aimed to examine the pooled prevalence of dyslipidemia among the Vietnamese adult population.</div></div><div><h3>Method</h3><div>Five databases, PubMed, Web of Science, Embase, CINAHL, Google Scholar, and local peer-reviewed journals were searched from inception to May 2024 without language restrictions. Pooled percentages of all dyslipidemia indicators were derived by random-effect model meta-analysis. We also estimated the pooled crude odds ratio and confidence interval (CI) for factors associated with dyslipidemia and calculated Hedges's g standardized mean for each dyslipidemia component.</div></div><div><h3>Results</h3><div>Sixty-nine studies were identified as relevant for systematic review, with 41 studies included in the meta-analysis. The overall prevalence of having at least one component of dyslipidemia was 49 % (95%CI = 38%–60 %), and figures for high total cholesterol, elevated triglycerides, increased low-density lipoprotein-cholesterol and low high-density lipoprotein-cholesterol were 31 % (95%CI = 25 %; 37 %), 38 % (95%CI = 31 %; 44 %), 21 % (95%CI = 12 %; 32 %), 23 % (95%CI = 16 %; 30 %), respectively. The pooled percentage of overall dyslipidemia was higher in males, in the Southeast region and in studies reported in Vietnamese than those in English. Having diabetes, hypertension, abdominal obesity and overweight/obesity were significantly positively associated with dyslipidemia.</div></div><div><h3>Conclusion</h3><div>The prevalence of dyslipidemia was substantially high and increased in the Vietnamese adult population. Findings from this up-to-date review reinforce the necessity of effective implementation of NCDs prevention to achieve the national goal.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103171"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placenta-derived biomaterials vs. standard care in chronic diabetic foot ulcer healing: A systematic review and meta-analysis","authors":"Maria Ruiz-Muñoz,&nbsp;Francisco-Javier Martinez-Barrios,&nbsp;Eva Lopezosa-Reca","doi":"10.1016/j.dsx.2024.103170","DOIUrl":"10.1016/j.dsx.2024.103170","url":null,"abstract":"<div><h3>Introduction</h3><div>This study explored the effectiveness of current placenta-derived biomaterials therapies in ulcer healing in DFU compared to standard of care (SOC).</div></div><div><h3>Methods</h3><div>The systematic review and meta-analysis were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. The electronic databases of PubMed, EMBASE, and Web of Science (WoS) internet were searched for the outcome rate of complete ulcer healing. The risk of bias assessment was conducted using the tool recommended by the Cochrane Collaboration. Statistical analysis included the individual and combined result of the studies, heterogeneity test, the effect size, sensitivity analysis, and publication bias tests.</div></div><div><h3>Results</h3><div>Twelve randomized controlled trials (RCTs) with a total of 833 patients were included in this study. This meta-analysis showed a higher rate of complete ulcer healing in groups receiving placenta-derived biomaterials therapies (OR = 6.247 [4.425, 8.819], p &lt; 0.01, I² = 41 %) compared to control groups.</div></div><div><h3>Conclusion</h3><div>Placenta-derived biomaterials therapies have been shown to be more effective for achieving complete ulcer healing compared to current conventional treatments in DFU.</div></div><div><h3>Implications for clinical practice</h3><div>The utilization of placenta-derived biomaterials in therapies for wound healing, particularly in chronic DFU, presents promising implications for clinical practice. These biomaterials offer a rich source of growth factors, cytokines, and extracellular matrix components, which can stimulate tissue regeneration and angiogenesis. Incorporating such therapies into clinical practice holds the potential to accelerate wound closure, reduce infection rates, and improve overall healing outcomes in people with diabetic chronic foot ulcers. Furthermore, the availability of these biomaterials can offer clinicians a readily-accessible and cost-effective alternative to traditional wound care approaches, ultimately enhancing patient care and quality of life.</div><div>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103170"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding the disproportionate risk factor landscape of global type 2 diabetes burden in adults: An attribution analysis from 1990 to 2050","authors":"Yue Huang ,&nbsp;Jingxuan Wang ,&nbsp;Lan Xu,&nbsp;Nannan Feng,&nbsp;Xihao Du,&nbsp;Meng Chen,&nbsp;Yiyuan Li,&nbsp;Guangrui Yang,&nbsp;Hui Wang,&nbsp;Victor W. Zhong","doi":"10.1016/j.dsx.2024.103181","DOIUrl":"10.1016/j.dsx.2024.103181","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited systematic assessments of risk factor contributions to the global burden of type 2 diabetes (T2D) across subpopulations hinder targeted policies and resource allocation.</div></div><div><h3>Materials and methods</h3><div>Utilizing the Global Burden of Disease study (GBD) 2019, we analyzed the disability-adjusted life-years (DALYs) for T2D attributable to 15 risk factors in adults (aged 25+ years) globally and by sex, age, Socio-demographic Index (SDI), and GBD region, from 1990 to 2019. Additionally, we assessed future trends of these risk factors through 2050.</div></div><div><h3>Results</h3><div>High body-mass index (BMI) emerged as the predominant risk factor in all subpopulations in 2019, with its impact projected to double by 2050. During 1990–2019, males were more affected by smoking, while females by secondhand smoke and household air pollution. The related DALYs increased with age, except for high BMI and smoking peaking at 60–74 years. In 2019, diet high in processed meat ranked second in high SDI regions, contrasting with household air pollution in low SDI regions. National disparities were observed, with Fiji recording the highest rates of DALYs related to both high BMI and dietary risks in 2019, which were approximately 50 and 15 times higher than those observed in Japan, respectively.</div></div><div><h3>Conclusions</h3><div>Tailored interventions targeting major contributing risk factors specific to each subpopulation are key to the success of the global combat against T2D.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103181"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}